Assembly Biosciences, Inc. (ASMB)
25.47
+0.03
(+0.12%)
USD |
NASDAQ |
Sep 22, 16:00
25.47
0.00 (0.00%)
After-Hours: 20:00
Assembly Biosciences Enterprise Value : 186.98M for Sept. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 21, 2026 | 186.98M |
| September 18, 2026 | 177.65M |
| September 17, 2026 | 185.00M |
| September 16, 2026 | 187.77M |
| September 15, 2026 | 200.28M |
| September 14, 2026 | 256.85M |
| September 11, 2026 | 273.53M |
| September 10, 2026 | 286.63M |
| September 09, 2026 | 334.47M |
| September 08, 2026 | 382.31M |
| September 04, 2026 | 408.51M |
| September 03, 2026 | 399.18M |
| September 02, 2026 | 410.89M |
| September 01, 2026 | 380.32M |
| August 31, 2026 | 349.55M |
| August 28, 2026 | 358.29M |
| August 27, 2026 | 372.78M |
| August 26, 2026 | 385.09M |
| August 25, 2026 | 383.30M |
| August 24, 2026 | 382.31M |
| August 21, 2026 | 364.44M |
| August 20, 2026 | 347.57M |
| August 19, 2026 | 353.72M |
| August 18, 2026 | 319.78M |
| August 17, 2026 | 277.70M |
| Date | Value |
|---|---|
| August 14, 2026 | 336.06M |
| August 13, 2026 | 276.51M |
| August 12, 2026 | 219.14M |
| August 11, 2026 | 223.31M |
| August 10, 2026 | 212.79M |
| August 07, 2026 | 211.60M |
| August 06, 2026 | 207.03M |
| August 05, 2026 | 208.72M |
| August 04, 2026 | 206.83M |
| August 03, 2026 | 185.39M |
| July 31, 2026 | 180.43M |
| July 30, 2026 | 199.29M |
| July 29, 2026 | 180.43M |
| July 28, 2026 | 189.56M |
| July 27, 2026 | 196.31M |
| July 24, 2026 | 189.16M |
| July 23, 2026 | 182.61M |
| July 22, 2026 | 198.89M |
| July 21, 2026 | 207.43M |
| July 20, 2026 | 179.44M |
| July 17, 2026 | 214.18M |
| July 16, 2026 | 194.92M |
| July 15, 2026 | 212.59M |
| July 14, 2026 | 213.18M |
| July 13, 2026 | 217.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 208.12B |
| BridgeBio Pharma, Inc. | 15.69B |
| ACADIA Pharmaceuticals, Inc. | 3.661B |
| Alnylam Pharmaceuticals, Inc. | 32.35B |
| Anika Therapeutics, Inc. | 263.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.857M |
| Revenue (Quarterly) | 13.37M |
| Total Expenses (Quarterly) | 17.23M |
| EPS Diluted (Quarterly) | -0.2046 |
| Gross Profit Margin (Quarterly) | 99.85% |
| Profit Margin (Quarterly) | -28.84% |
| Earnings Yield | -0.29% |
| Normalized Earnings Yield | -0.2886 |